As survival regulation is a key process in multiple myeloma biology, we have studied the Bcl-2 family proteins that can be regulated by three myeloma cell survival factors: interleukin-6 (IL-6), ...
A blood test is a medical procedure where a sample of a person's blood is taken (called a blood draw) and sent to a lab for analysis. Knowing the results of blood tests helps a physician better ...
How Does Blenrep Work for Multiple Myeloma? Blenrep is an antibody-drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs contain two parts, a protein called an antibody and an ...
Multiple myeloma accounts for roughly 10% of blood cancers and has only a 53% five-year survival rate. Although treatments for myeloma patients have greatly improved within the past two decades, the ...
Researchers have found that cells from a blood-borne cancer called multiple myeloma rely on the activity of a single protein, IRF4, for the activation of a wide range of genes responsible for cell ...
Strong positive results of a novel combination of two immunotherapy drugs as a treatment for multiple myeloma after other treatments have failed suggest the combination could be a “functional cure,” ...
A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...
Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific ...
Myeloma, also called multiple myeloma, is a cancer of plasma cells in the bone marrow. It can be quiet at first, showing up as back pain, fatigue, frequent infections or no symptoms at all. That ...
While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...
Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...